Cell:miR-124可能成为肝癌治疗新靶标

2012-03-10 MedSci MedSci原创

 近日来自美国哈佛医学院达纳法癌症研究所(Dana-Farber Cancer Institute)的研究人员通过小鼠模型发现了一种可触发肝脏炎症,促使正常细胞转化为癌细胞的分子机制,并证实一种特殊的micro-RNA——miR-124可用于预防和治疗肝癌。相关研究论文在线发表在12月9日的《细胞》(Cell)杂志上。[An HNF4α-miRNA Inflammatory Feedba

 近日来自美国哈佛医学院达纳法癌症研究所(Dana-Farber Cancer Institute)的研究人员通过小鼠模型发现了一种可触发肝脏炎症,促使正常细胞转化为癌细胞的分子机制,并证实一种特殊的micro-RNA——miR-124可用于预防和治疗肝癌。相关研究论文在线发表在12月9日的《细胞》(Cell)杂志上。[An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis.Cell, Volume 147, Issue 6, 1233-1247, 9 December 2011]


肝癌是最常见的肿瘤类型,在世界范围内肿瘤相关性死亡因素中排名第三,全球每年有超过50万新患者。环境因素及慢性感染例如慢性肝炎被视为是导致肝癌的重要病因,然而直到现在科学家们对于其关联的分子机制仍知之甚少。

在这篇文章中,达纳法癌症研究所癌症免疫学及艾滋病系Dimitrios Iliopoulos及同事发现小鼠在接触强致癌化合物二乙基亚硝胺(DEN)后,细胞中的分子环路受到了激活,促使细胞进入炎症状态。一旦这一炎症环路被开启,即使只有几天的时间,也将使得细胞陷入到永无止境的反馈环中,从而产生出“滚雪球效应”( snowball effect),最终导致了肝癌形成。

此前,Iliopoulos课题组曾在乳腺癌中发现过相似的反馈回路,并证实一种特殊的microRNA——miR-124是该回路的关键元素。在新研究中,Iliopoulos等发现癌细胞中miR-124和反馈回路中的另一关键因子HFN4α的活性均受到了显著抑制。HFN4α是在肝细胞生成和正常生物功能维持中起关键性作用的重要因子。研究人员证实当HNF4α受到抑制时,细胞进入到临时的炎症状态。仅在数天时间内,这一临时的炎症反应便借助于反馈回路持续放大转化为了慢性炎症反应。

由于HNF4α 和 miR-124之间存在相互作用,科学家们于是猜想提高miR-124的活性或可恢复HNF4α正常活性,终止失控的炎性反馈,抑制肿瘤生长。为了检验这一猜想,研究人员对DEN处理的肝癌模型小鼠给予每周一次的miR-124治疗。在连续治疗4周后,研究人员证实miR-124通过诱导癌细胞自毁的方式抑制了超过80%的肿瘤生长。此外,他们还证实该治疗未引起其他重要脏器例如肾脏、脾脏、心肺的毒副作用。

“这是我们首次证实miR-124可预防和治疗肝癌,”Iliopoulos说:“我们希望未来miR-124能够用于高风险人群例如慢性丙型肝炎患者预防肝癌,或是作为肝癌患者的治疗药物。”目前Iliopoulos正计划于2012年启动miR-124对肝癌的I期临床试验。
{nextpage}
 
相关阅读:
文章标题:An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis.
文章来源:Cell. 2011 Dec 9;147(6):1233-47.
期刊影响因子32.401

肝癌——全球第三大癌症死亡的原因——可由环境暴露或感染慢性肝炎引起,但迄今为止,人们对它们之间的联系知之甚少。

日前,美国达纳法伯(Dana-Farber)癌症研究所的研究人员利用小鼠模型发现了一种能够触发肝脏炎症和促使正常细胞转换为癌细胞的机制。此外,它们在小鼠中找到了一个特定的micro-RNA(miR-124)——新近发现的一类分子调节器的成员——能够用于治疗或甚至阻止肝癌发生。

“在这个研究中,我们首次描述mirco-RNA,确定其能够阻止和治疗癌症,”Dimitrios Iliopoulos说,他是达纳法伯癌症免疫和艾滋病部门的成员。这项研究结果发表在12月9日的Cell杂志上。作者说他们计划在2012年对肝癌患者使用miR-124开始I期临床试验。
Cell:一种新型肝癌治疗方法将于明年进入临床试验 肝癌 治疗 临床试验 miR-124 HFN4α
图 miR-124—HFN4α通路在肝细胞中

Iliopoulos和他的同事发现,小鼠接触致癌的化学物二乙基亚硝胺(DEN)后,通过活化分子电路,建立细胞炎症状态,最终形成肝癌。一旦这种炎症电路被打开,即使只需要短短几天时间,它就变成不可逆的,通过一个永无止境的反馈回路维持它的活性,Iliopoulos把它称为“雪球效应”。

Iliopoulos在先前的试验中发现了一个类似的反馈电路(与乳腺癌的发生有关)。达纳法伯的小组所报道电路的一个元素就是micro-RNA,称为miR-124。

Micro-RNAs是极其短的RNA,其作为一种信使分子帮助细胞根据DNA的指令构建蛋白,而不是翻译成蛋白。最近认为MiRNAs与人类疾病(包括各种癌症)的发病机制有关。达纳法伯小组发现miR-124和另一个反馈电路的关键控制因子HNF4α,在癌细胞中的活性下降。

HFN4α是生成肝细胞和维持它们正常生物功能的一个重要因子。Iliopoulos表示,当HNF4α被抑制,它制造细胞炎症的临时状态——癌症的前身。“仅在几天之后,通过这个持续放大的反馈电路,这种短暂的炎症应答转变成为一种慢性炎症应答,”他说。

由于HNF4α和miR-124互相作用,科学家假设促进miR-124活性可能会恢复HNF4α的正常活性,终止失控的炎症周期,让肿瘤停止生长。

为了验证这个想法,他们给予通过接触CEN患肝癌的小鼠体系miR-124,每周一次共四周。“我们发现miR-124抑制了超过80%的肿瘤生长速度和生长大小”,这种结果是通过诱发癌细胞自我毁灭实现的。同时,研究者们观察到,它对其他重要器官,如肾脏、脾脏、心脏和肺都没有毒性作用。

进一步地,他们表明给予miR-124的小鼠暴露在DEN下,事实上阻止了肝癌的发展。

“我们希望miR-124能够被用于具有潜在罹患肝癌的高风险人群,例如慢性丙型肝炎患者。或是作为肝癌患者的一种治疗剂,”Iliopoulos说。

文章编译自:Novel Therapeutic Approach for Liver Cancer Identified. ScienceDaily. 2011.12.9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958681, encodeId=49d2195868123, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Aug 11 01:59:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868468, encodeId=c569186846863, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 14 09:59:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930340, encodeId=2faa193034077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 12 10:59:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037317, encodeId=cd77203e317cb, content=<a href='/topic/show?id=c19381284ca' target=_blank style='color:#2F92EE;'>#肝癌治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81284, encryptionId=c19381284ca, topicName=肝癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Dec 18 16:59:00 CST 2012, time=2012-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352689, encodeId=31ef13526890c, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 12 12:59:00 CST 2012, time=2012-03-12, status=1, ipAttribution=)]
    2012-08-11 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958681, encodeId=49d2195868123, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Aug 11 01:59:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868468, encodeId=c569186846863, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 14 09:59:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930340, encodeId=2faa193034077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 12 10:59:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037317, encodeId=cd77203e317cb, content=<a href='/topic/show?id=c19381284ca' target=_blank style='color:#2F92EE;'>#肝癌治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81284, encryptionId=c19381284ca, topicName=肝癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Dec 18 16:59:00 CST 2012, time=2012-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352689, encodeId=31ef13526890c, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 12 12:59:00 CST 2012, time=2012-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958681, encodeId=49d2195868123, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Aug 11 01:59:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868468, encodeId=c569186846863, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 14 09:59:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930340, encodeId=2faa193034077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 12 10:59:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037317, encodeId=cd77203e317cb, content=<a href='/topic/show?id=c19381284ca' target=_blank style='color:#2F92EE;'>#肝癌治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81284, encryptionId=c19381284ca, topicName=肝癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Dec 18 16:59:00 CST 2012, time=2012-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352689, encodeId=31ef13526890c, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 12 12:59:00 CST 2012, time=2012-03-12, status=1, ipAttribution=)]
    2012-06-12 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958681, encodeId=49d2195868123, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Aug 11 01:59:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868468, encodeId=c569186846863, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 14 09:59:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930340, encodeId=2faa193034077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 12 10:59:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037317, encodeId=cd77203e317cb, content=<a href='/topic/show?id=c19381284ca' target=_blank style='color:#2F92EE;'>#肝癌治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81284, encryptionId=c19381284ca, topicName=肝癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Dec 18 16:59:00 CST 2012, time=2012-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352689, encodeId=31ef13526890c, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 12 12:59:00 CST 2012, time=2012-03-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958681, encodeId=49d2195868123, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Aug 11 01:59:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868468, encodeId=c569186846863, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Aug 14 09:59:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930340, encodeId=2faa193034077, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 12 10:59:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037317, encodeId=cd77203e317cb, content=<a href='/topic/show?id=c19381284ca' target=_blank style='color:#2F92EE;'>#肝癌治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81284, encryptionId=c19381284ca, topicName=肝癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Dec 18 16:59:00 CST 2012, time=2012-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352689, encodeId=31ef13526890c, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 12 12:59:00 CST 2012, time=2012-03-12, status=1, ipAttribution=)]
    2012-03-12 zhaojie88